ARA-290 news and clinical trials

A review and case report published in Frontiers in oral health examined the use of regenerative peptides like BPC-157, TB-500, and ARA-290 for inferior alveolar nerve injury. The authors reported neurosensory recovery in three clinical cases but cautioned that causality cannot be established.

A review of pharmacological treatments for diabetic neuropathy analyzed roughly 107 articles on approved and experimental therapies. The study highlighted that while agents like Cibinetide show potential for nerve repair, current treatments mostly focus on symptom management.

A narrative review summarized the current evidence on regenerative peptides used for chronic pain management. The authors concluded that clinical evidence in humans remains limited and most of these therapies currently lack FDA approval.

Researchers tested the peptide ARA-290 in a mouse model of type 2 diabetes to evaluate cognitive dysfunction. The study found that while ARA-290 improved insulin sensitivity and circulating monocyte proportions, it did not restore executive cognitive flexibility.

Molecular medicine issued a retraction for a study on the peptide pHBSP and its ability to attenuate acute kidney injury.

A review published in Frontiers in neurology evaluated four engineered erythropoietin derivatives, including cibinetide, for the treatment of traumatic brain injury. The authors found that meta-analyses suggest potential for reduced mortality but noted that functional benefits remain unproven.